Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease.
Intern Med
; 61(4): 585-589, 2022 Feb 15.
Article
in English
| MEDLINE | ID: covidwho-1690565
ABSTRACT
With expansion of the COVID-19 pandemic, reports of post-COVID-19 interstitial lung disease (ILD) have been emerging. However, there are few reports regarding treatment. Some reports indicate that corticosteroids are effective for post-COVID-19 ILD, but the use of long-term corticosteroid carries risks of side effects. We administered tacrolimus to an elderly patient with post-COVID-19 ILD who suffered a respiratory failure relapse during steroid tapering. The respiratory status improved with tacrolimus in the post-acute phase, but pulmonary fibrosis progressed in the late phase. Tacrolimus may be effective for treating post-COVID-19 ILD in the post-acute phase, but it does not halt progression of pulmonary fibrosis.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Lung Diseases, Interstitial
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Aged
/
Humans
Language:
English
Journal:
Intern Med
Journal subject:
Internal Medicine
Year:
2022
Document Type:
Article
Affiliation country:
INTERNALMEDICINE.7971-21
Similar
MEDLINE
...
LILACS
LIS